Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335589 | 1.00 | TOP2A (0.44) | TOP2AALDH1A1CYP1A2HSD17B10CYP2C9 | |
| SCHEMBL335482 | 0.95 | TOP2A (0.40) | TOP2A | |
| SCHEMBL3360410 | 0.91 | TOP2A (0.38) | TOP2A | |
| SCHEMBL19707029 | 0.85 | TOP2A (0.42) | TOP2AALDH1A1CYP1A2HSD17B10CYP2C9 | |
| SCHEMBL336280 | 0.85 | TOP2A (0.39) | TOP2AALDH1A1CYP1A2CYP2C9CLK4 | |
| SCHEMBL10128106 | 0.84 | TOP2A (0.42) | TOP2AALDH1A1CYP1A2HSD17B10CYP2C9 | |
| SCHEMBL21372391 | 0.82 | TOP2A (0.33) | TOP2A | |
| SCHEMBL19707025 | 0.82 | TOP2A (0.41) | TOP2AALDH1A1CYP1A2HSD17B10CYP2C9 | |
| SCHEMBL21372395 | 0.81 | TOP2A (0.32) | TOP2A | |
| SCHEMBL21935843 | 0.80 | TOP2A (0.44) | TOP2AALDH1A1CYP1A2HSD17B10CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10633366-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-04-28 | — | — | US | disclosed |
| US-10633366-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-04-28 | — | — | US | disclosed |
| EP-3468975-B1 | NEW ANTIBACTERIAL COMPOUNDS | ACRAF (IT) | 2020-04-01 | — | — | EP | disclosed |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-03-26 | — | — | US | disclosed |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-03-26 | — | — | US | disclosed |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-08-22 | — | — | US | disclosed |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-08-22 | — | — | US | disclosed |
| EP-3468970-A1 | NEW ANTIBACTERIAL COMPOUNDS | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017211760-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211759-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211759-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211760-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| WO-2016027249-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-25 | — | — | WO | disclosed |
| US-8389524-B2 | Tricyclic nitrogen containing compounds as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8389524-B2 | Tricyclic nitrogen containing compounds as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20100137282-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | TOP2A 1337/4885ALDH1A1 4199/4885CYP1A2 4147/4885 |
| US-10633366-B2 | Antibacterial compounds | MRPL21, LAS1L, MRPL19 | TOP2A 398/4885ALDH1A1 784/4885CYP1A2 584/4885 |
| US-20100137282-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | ZYX, NRDC, NAA50 | TOP2A 85/4885ALDH1A1 4522/4885CYP1A2 2262/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | TOP2A 46/4885ALDH1A1 300/4885CYP1A2 202/4885 |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | TOP2A 1337/4885ALDH1A1 4199/4885CYP1A2 4147/4885 |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | TOP2A 376/4885ALDH1A1 2255/4885CYP1A2 792/4885 |
| US-10640488-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | TOP2A 905/4885ALDH1A1 3914/4885CYP1A2 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.